

## Core BLAZE Product References



Farzaneh, E., Nia, F. R., Mehrtash, M., Mirmoeini, F. S., & Jalilvand, M. (2014). The Effects of 8-week *Nigella sativa* Supplementation and Aerobic Training on Lipid Profile and VO<sub>2</sub> max in Sedentary Overweight Females. *International journal of preventive medicine*, 5(2), 210–216.

Namazi, N., Larijani, B., Ayati, M. H., & Abdollahi, M. (2018). The effects of *Nigella sativa* L. on obesity: A systematic review and meta-analysis. *Journal of ethnopharmacology*, 219, 173–181. <https://doi.org/10.1016/j.jep.2018.03.001>

Razmpoosh, E., Safi, S., Mazaheri, M. *et al.* Effects of oral *Nigella sativa* oil on the expression levels and serum concentrations of adiponectin, PPAR- $\gamma$ , and TNF- $\alpha$  in overweight and obese women: a study protocol for a crossover-designed, double-blind, placebo-controlled randomized clinical trial. *Trials* 20, 512 (2019). <https://doi.org/10.1186/s13063-019-3568-0>

Nowak, A., Zakłós-Szyda, M., Błasiak, J., Nowak, A., Zhang, Z., & Zhang, B. (2019). Potential of *Schisandra chinensis* (Turcz.) Baill. in Human Health and Nutrition: A Review of Current Knowledge and Therapeutic Perspectives. *Nutrients*, 11(2), 333. <https://doi.org/10.3390/nu11020333>

Zeng, K. W., Zhang, T., Fu, H., Liu, G. X., & Wang, X. M. (2012). Schisandrin B exerts anti-neuroinflammatory activity by inhibiting the Toll-like receptor 4-dependent MyD88/IKK/NF- $\kappa$ B signaling pathway in lipopolysaccharide-induced microglia. *European journal of pharmacology*, 692(1-3), 29–37. <https://doi.org/10.1016/j.ejphar.2012.05.030>

Pan, S. Y., Dong, H., Zhao, X. Y., Xiang, C. J., Fang, H. Y., Fong, W. F., Yu, Z. L., & Ko, K. M. (2008). Schisandrin B from *Schisandra chinensis* reduces hepatic lipid contents in hypercholesterolaemic mice. *The Journal of pharmacy and pharmacology*, 60(3), 399–403. <https://doi.org/10.1211/jpp.60.3.0017>

Kwon, D. Y., Kim, D. S., Yang, H. J., & Park, S. (2011). The lignan-rich fractions of Fructus Schisandrae improve insulin sensitivity via the PPAR- $\gamma$  pathways in in vitro and in vivo studies. *Journal of ethnopharmacology*, 135(2), 455–462.

<https://doi.org/10.1016/j.jep.2011.03.037>

Wan-Loy, C., & Siew-Moi, P. (2016). Marine Algae as a Potential Source for Anti-Obesity Agents. *Marine drugs*, 14(12), 222. <https://doi.org/10.3390/md14120222>

Sharma, B. R., Kim, H. J., Kim, M. S., Park, C. M., & Rhyu, D. Y. (2017). Caulerpa okamurae extract inhibits adipogenesis in 3T3-L1 adipocytes and prevents high-fat diet-induced obesity in C57BL/6 mice. *Nutrition research (New York, N.Y.)*, 47, 44–52.

<https://doi.org/10.1016/j.nutres.2017.09.002>

Buchanan, B., Meng, Q., Poulin, M. M., Zuccolo, J., Azike, C. G., Gabriele, J., & Baranowski, D. C. (2018). Comparative pharmacokinetics and safety assessment of transdermal berberine and dihydroberberine. *PLoS one*, 13(3), e0194979. <https://doi.org/10.1371/journal.pone.0194979>

Cicero AFG, Colletti A, Bajraktari G, et al. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. *Arch Med Sci*. 2017;13(5):965-1005. PMID: [28883839](https://pubmed.ncbi.nlm.nih.gov/28883839/).

Li, Y., Wang, P., Zhuang, Y., Lin, H., Li, Y., Liu, L., Meng, Q., Cui, T., Liu, J., & Li, Z. (2011). Activation of AMPK by berberine promotes adiponectin multimerization in 3T3-L1 adipocytes. *FEBS letters*, 585(12), 1735–1740. <https://doi.org/10.1016/j.febslet.2011.04.051>

Chen, C., Zhang, Y., & Huang, C. (2010). Berberine inhibits PTP1B activity and mimics insulin action. *Biochemical and biophysical research communications*, 397(3), 543–547.

<https://doi.org/10.1016/j.bbrc.2010.05.153>

Feng, R., Shou, JW., Zhao, ZX. *et al.* Transforming berberine into its intestine-absorbable form by the gut microbiota. *Sci Rep* 5, 12155 (2015). <https://doi.org/10.1038/srep12155>

Rogers, J., Urbina, S. L., Taylor, L. W., Wilborn, C. D., Purpura, M., Jäger, R., & Juturu, V. (2018). Capsaicinoids supplementation decreases percent body fat and fat mass: adjustment using covariates in a post hoc analysis. *BMC obesity*, 5, 22. <https://doi.org/10.1186/s40608-018-0197-1>

Zheng, J., Zheng, S., Feng, Q., Zhang, Q., & Xiao, X. (2017). Dietary capsaicin and its anti-obesity potency: from mechanism to clinical implications. *Bioscience reports*, 37(3), BSR20170286. <https://doi.org/10.1042/BSR20170286>

McCarty, M. F., DiNicolantonio, J. J., & O'Keefe, J. H. (2015). Capsaicin may have important potential for promoting vascular and metabolic health. *Open heart*, 2(1), e000262.

<https://doi.org/10.1136/openhrt-2015-000262>

---

Ostojic S. M. (2006). Yohimbine: the effects on body composition and exercise performance in soccer players. *Research in sports medicine (Print)*, 14(4), 289–299.  
<https://doi.org/10.1080/15438620600987106>

Taouis M, et al. [Mechanism of the lipid-mobilizing effect of alpha-2 adrenergic antagonists in the dog](#). *J Pharmacol Exp Ther.* (1988)

Rimmele U, et al. [Trained men show lower cortisol, heart rate and psychological responses to psychosocial stress compared with untrained men](#). *Psychoneuroendocrinology.* (2007)

Cameron OG, et al. [Effects of yohimbine on cerebral blood flow, symptoms, and physiological functions in humans](#). *Psychosom Med.* (2000)